Company news
Psyence Group Inc. (CSE:PSYG) news
Psyence Group Inc. news releases on 6ix. Latest, May 21, 2026: Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders
Press releases & updates
Psyence Group Inc. Announces Results of Annual General and Special Meeting of Shareholders
May 21, 2026
Psyence Group Inc. Provides Update on Proposed Amalgamation with GoldCoast Resource Corp.
March 17, 2026
Psyence Group Inc. Enters into Amending Agreement to Extend Amalgamation Timeline with GoldCoast Resource Corp.
February 24, 2026
Psyence Group's RTO Target, GoldCoast Resource Corp., Granted Offshore Reconnaissance License for Gold Exploration on Ghana's Shallow Continental Shelf
January 27, 2026
Psyence Group Inc. Enters into Amalgamation Agreement with Goldcoast Resource Corp.
November 24, 2025
Psyence : Announces RSU Grants
October 20, 2025
Psyence Group Inc. Announces RSU Grants
October 17, 2025
Psyence : Enters Into A Letter Of Intent To Acquire Goldcoast Resource Corp.
October 6, 2025
Psyence Group Inc. Enters Into a Letter of Intent to Acquire Goldcoast Resource Corp.
August 22, 2025
Psyence Group Inc. Closes Second Tranche of Non‑Brokered Private Placement for Remaining Proceeds
July 7, 2025
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
June 25, 2025
PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares
June 18, 2025
Psyence : Announces Share Consolidation
June 5, 2025
Psyence Group Announces Share Consolidation
April 17, 2025
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein
March 25, 2025
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
March 10, 2025
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
December 6, 2024
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
October 31, 2024
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
October 14, 2024
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
September 20, 2024
Psyence : NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
May 6, 2024
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
March 26, 2024